Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study-Reference-Cited by-同舟云学术

Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study

Published:2024-04 Issue: Volume:151 Page:106739
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Kim Dong Hyun,Lim Seung Taek,Kim Hye Ryun,Kang Eun Joo,Ahn Hee Kyung,Lee Yun-Gyoo,Sun Der Sheng,Kwon Jung Hye,Lee Sang-Cheol,Lee Hyun Woo,Kim Min Kyoung,Keam Bhumsuk^ORCID,Park Keon-Uk,Shin Seong-Hoon,Yun Hwan Jung

Funder

Ministry of Health and Welfare

AstraZeneca

Publisher

Elsevier BV

Reference56 articles.

1. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019;Kocarnik;JAMA Oncol,2022

2. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment;Marur,2016

3. Optimal treatment for recurrent/metastatic head and neck cancer;Vermorken;Ann Oncol,2010

4. Pembrolizumab for the treatment of non–small-cell lung cancer;Garon;N Engl J Med,2015

5. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2024-08